Eugia recalls one lot of vancomycin injection to the hospital level for glass particulate
Published November 8, 2026 · Coverage November 1–7, 2026, Pacific · High priority
Eugia US LLC announced a voluntary nationwide recall of one lot (3VM26026A) of Vancomycin Hydrochloride for Injection USP (United States Pharmacopeia) 1.25g/Vial-30mL to the hospital/healthcare facility/user level because a glass particle was identified inside a vial. The company announcement is dated November 6, 2026; FDA's publish date is November 9, 2026. The company says the entire lot shipped to wholesalers nationwide from September 2 through September 15, 2026, and that it has not received any adverse event reports. Holders of the lot are told to discontinue use and quarantine it immediately.
Background
Vancomycin hydrochloride for injection is a glycopeptide antibacterial indicated in adult and pediatric patients, neonates and older, for the treatment of septicaemia, infective endocarditis, skin and skin structure infections, bone infections and lower respiratory tract infections. When a company announces a recall, FDA posts the company's announcement as a public service and does not endorse the product or the company; the announcement says this recall is being conducted with FDA's knowledge.
Who this affects
Hospitals, health-system pharmacies and infusion sites holding Eugia vancomycin hydrochloride for injection 1.25 g vials, lot 3VM26026A.
Why it matters
The company says there is a reasonable probability that use of product containing glass particulates can cause serious adverse health consequences such as blockage and clotting in blood vessels, and that greater susceptibility may exist in neonates, infants and patients with compromised organ function. Operational reading: pharmacy should search inventory (including automated dispensing cabinets and satellite pharmacies) for National Drug Code (NDC) 55150-471-01 / 55150-471-10, lot 3VM26026A, quarantine any units, and arrange return. Inference: substitution planning may be needed if the lot was a significant share of vancomycin stock.
Required actions
- None stated as a legal requirement; the company announcement directs holders of the lot to discontinue use and quarantine immediately (2026-11-06 announcement).
Recommended action
- Search all pharmacy locations and cabinets for lot 3VM26026A and quarantine
- Inform clinicians of the recall as the announcement asks
- Document the recall response in the drug recall log
Scope and timing
- Authority status
- Other (company-initiated voluntary recall announcement posted by FDA)
- Responsible owner
- Pharmacy
- Publication date
- 2026-11-09 (FDA publish date)
- Other dates
- 2026-11-06 company announcement date; lot shipped 2026-09-02 to 2026-09-15
Not established
FDA recall classification not yet established (not in the openFDA drug enforcement records for this edition's coverage week).
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →